A major challenge in the treatment of diseases is the selective transport of active agents to the damaged tissue or organ. Cell membranes are the most important barriers for a targeted drug delivery. Another problem is the degradation or derivatization of free agents in the body which often reduces the specific effect of the drug at the target site. Also, active agents are distributed incorrectly or are changed in the body, which may lead to unwanted side effects. An already-tested way to circumvent these disadvantages is the manufacturing of particulate active ingredient formulations, where the active agent is bound into a polymeric shell or matrix.
Development of an intranasal form of therapy for the treatment of multiple sclerosis
In the EU-funded research project “N2B-patch”, an international consortium is developing an intranasal application platform for biopharmaceutics against diseases of the central nervous system (CNS). Using the treatment of multiple sclerosis as an example, the "Nose2Brain“ approach intends to transport active substances formulated in biomaterials directly through the nose to the brain.
Duration: January 2017 – December 2020